.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,716,932

« Back to Dashboard

Details for Patent: 5,716,932

Title: Process for the long term reduction of body fat stores, insulin resistance, and hyperinsulinemia in vertebrates
Abstract:A process for the long term modification and regulation of lipid metabolism--generally to reduce obesity, insulin resistance, and hyperinsulinemia (the three hallmarks of Type II diabetes)--by injections into the bloodstream of a vertebrate, animal or human, of prolactin, or both prolactin and a glucocorticosteroid. The injections are made over a limited period at a time of day dependent on the normal circadian rhythm of fat and lean members of a similar species. Decreases (or increases) in body fat deposits result by treatment of an obese species (lean species) on a daily timed sequence based on circadian rhythms of the peak prolactin, or peak prolactin and peak glucocorticosteroid, blood level established for lean members (or obese members) of a similar species. Insulin resistance, and hyperinsulinemia can also be controlled in humans on a long term basis by treatment corresponding to that of the treatment for obesity. The short term daily injections reset hormonal timing in the neural centers of the brain to produce long term effects.
Inventor(s): Meier; Albert H. (Baton Rouge, LA), Cincotta; Anthony H. (Baton Rouge, LA)
Assignee: Louisiana State University and Agricultural and Mechanical College (Baton Rouge, LA)
Filing Date:May 26, 1995
Application Number:08/450,917
Claims:1. A method for modifying an aberrant glucose metabolism in a human in need of treatment comprising administering prolactin into the blood stream of said human at a predetermined time within the daily interval at which the prolactin level in the bloodstream of a lean insulin-sensitive human reaches its peak value, thereby achieving at least one of the following: reduction of hyperinsulinemia decrease in insulin resistance, and reduced plasma insulin levels.

2. The method of claim 1 wherein the modification persists after cessation of said prolactin administration.

3. The method of claim 1 further comprising administering a glucocorticosteroid to said human.

4. The method of claim 3 wherein said glucocorticosteroid is administered daily at a second predetermined time of day, said second time being within the daily time interval at which the glucocorticosteroid level of a lean insulin-sensitive human reaches its peak value.

5. The method of claim 1 wherein prolactin is administered once a day at dosage levels ranging from about 175 micrograms to about 2000 micrograms, per pound of body weight.

6. The method of claim 4 wherein the prolactin is administered at dosage levels ranging from about 175 micrograms to about 2000 micrograms per pound body weight, and glucocorticosteroid is administered at dosage levels ranging from about 175 micrograms to about 2000 micrograms, per pound body weight.

7. The method of claim 4 wherein the glucocorticosteroid is cortisol.

8. The method of claim 1 wherein the prolactin is administered daily at said predetermined time.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc